Sudden gains in the treatment of obsessive-compulsive disorder

Psychother Psychosom. 2012;81(1):44-51. doi: 10.1159/000329995. Epub 2011 Nov 22.

Abstract

Background: The present study examined sudden gains during treatment for obsessive-compulsive disorder (OCD) and their relationship to short- and long-term outcome.

Methods: Ninety-one individuals (age 19-64) completed either cognitive treatment, exposure treatment, or their combination with fluvoxamine for OCD. Participants' obsessive-compulsive symptoms were assessed before each weekly treatment session. In addition, obsessive-compulsive and depressive symptoms were assessed pre treatment and post treatment as well as 12 months following treatment termination.

Results: Sudden gains were found among 34.1% of participants and constituted 65.5% of the total reduction in obsessive-compulsive symptoms. Compared to individuals who did not experience sudden gains, individuals who experienced sudden gains reported lower levels of OCD symptoms post treatment, and this was maintained during follow-up.

Conclusions: Sudden gains are common in treatments for OCD and are predictive of treatment outcome and follow-up. Sudden gains mark a distinct trajectory of response to treatment for OCD. Individuals with sudden gains greatly improve during treatment and maintain their gains during follow-up, whereas individuals without sudden gains improve to a significantly lesser extent. Thus, treatment planning and development can benefit from considering sudden gains and the intra-individual course of improvement.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Analysis of Variance
  • Cognitive Behavioral Therapy*
  • Combined Modality Therapy
  • Depression / psychology*
  • Female
  • Fluvoxamine / therapeutic use
  • Follow-Up Studies
  • Humans
  • Implosive Therapy*
  • Male
  • Middle Aged
  • Obsessive-Compulsive Disorder / psychology
  • Obsessive-Compulsive Disorder / therapy*
  • Outcome Assessment, Health Care / statistics & numerical data*
  • Psychiatric Status Rating Scales / statistics & numerical data
  • Regression Analysis
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Time Factors
  • Young Adult

Substances

  • Fluvoxamine
  • Selective Serotonin Reuptake Inhibitors